Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Inactivation of Hepatic CYP2E1 by an Epoxide of Diallyl Sulfone

Peter D. Premdas, Raymond J. Bowers and Poh-Gek Forkert
Journal of Pharmacology and Experimental Therapeutics June 2000, 293 (3) 1112-1120;
Peter D. Premdas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond J. Bowers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Poh-Gek Forkert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Diallyl sulfone (DASO2) inhibits hepatic CYP2E1. In this investigation, we have tested the hypothesis that an epoxide formed from DASO2 is responsible for inactivation of hepatic CYP2E1 in mice. An epoxide of DASO2(1,2-epoxypropyl-3,3′-sulfonyl-1′-propene; DASO3) was synthesized and conjugated to glutathione (GSH) to produce the conjugates S-(1R,S-[[ 1-hydroxymethyl-2,3′-sulfonyl]-1′-propenyl]ethyl)glutathione (diastereomers) andS-(1-[[2R,S-hydroxypropyl]-3,3′-sulfonyl]-1′-propenyl)glutathione (diastereomers). Their identities were confirmed by 1H NMR analysis, and these were used as analytical standards. HPLC analysis revealed a major peak for the GSH conjugates that eluted at 20.5 min. This peak was detected in liver microsomal incubations performed with DASO2 in the presence of NADPH. A similar peak also was detected in incubations of CYP2E1-expressed lymphoblastoid microsomes, NADPH and DASO2. The generation of the epoxide-derived GSH conjugates in the microsomal incubations was concentration-dependent, and reached saturation at 0.75 to 1.0 mM DASO2. Formation of the conjugates was also time-dependent and peaked at 2.0 h after DASO2. Levels of DASO3 formed from DASO2, as estimated by production of a 4-(p-nitrobenzyl)pyridine derivative, were maximal at 1 mM DASO2 at 30 min. CYP2E1-dependentp-nitrophenol hydroxylase activity was decreased in microsomes incubated with DASO2, with alterations that were proportional to the concentration of DASO2 (0.25–1.0 mM) used. Dose-dependent decreases in hydroxylase activity also were found in microsomes from mice treated in vivo with DASO2 (25–200 mg/kg). These DASO2-induced decreases corresponded with reduced amounts of immunodetectable CYP2E1. Levels of spectrally detectable P450 and heme were both diminished by DASO2. These results supported the contention that an epoxide formed from DASO2 mediates the inactivation of hepatic CYP2E1.

Footnotes

  • Send reprint requests to: Dr. Poh-Gek Forkert, Department of Anatomy and Cell Biology, Queen's University, Kingston, Ontario, Canada K7L 3N6. E-mail: forkertp{at}post.queensu.ca

  • ↵1 This study was supported by Grant MT-11706 from the Medical Research Council of Canada, Grant 011129 from the National Cancer Institute of Canada, and Grant RO1-CA73220-01 from the U.S. National Cancer Institute (to P.G.F.).

  • Abbreviations:
    DAS
    diallyl sulfide
    GSH
    glutathione
    DASO
    diallyl sulfoxide
    DASO2
    diallyl sulfone
    DASO3
    1,2-epoxypropyl-3,3′-sulfonyl-1′-propene
    NBP
    4-(p-nitrobenzyl)pyridine
    mAb
    monoclonal antibody
    PNP
    p-nitrophenol
    TFA
    trifluoroacetic acid
    PAGE
    polyacrylamide gel electrophoresis
    ethyl DDC
    4-ethyl-3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine
    • Received November 5, 1999.
    • Accepted February 9, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 293 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 293, Issue 3
1 Jun 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inactivation of Hepatic CYP2E1 by an Epoxide of Diallyl Sulfone
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Inactivation of Hepatic CYP2E1 by an Epoxide of Diallyl Sulfone

Peter D. Premdas, Raymond J. Bowers and Poh-Gek Forkert
Journal of Pharmacology and Experimental Therapeutics June 1, 2000, 293 (3) 1112-1120;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Inactivation of Hepatic CYP2E1 by an Epoxide of Diallyl Sulfone

Peter D. Premdas, Raymond J. Bowers and Poh-Gek Forkert
Journal of Pharmacology and Experimental Therapeutics June 1, 2000, 293 (3) 1112-1120;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Transport Is Not Rate-Limiting in Morphine Glucuronidation in the Single-Pass Perfused Rat Liver Preparation
  • Enhanced Hepatic Uptake and Bioactivity of Type α1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol
  • Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Show more ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics